@article{9bd3a767b7a349198e18e18ce53c323c,
title = "Grand challenges for medical physics in radiation oncology",
abstract = "Medical physics has made considerable contributions to recent advances in radiation oncology. Medical physicists are key players in the clinical and scientific radiation oncology context due to their unique skill sets, flexibility, clinical involvement and intrinsic translational character. The continuing development and widespread adoption of {"}high-tech{"} radiotherapy has led to an increased need for medical physics involvement. More recently, our field is rapidly changing towards an era of {"}precision oncology{"}. These changes have opened new challenges for the definition of the professional and scientific roles and responsibilities of medical physicists. In this paper, we have identified four grand challenges of medical physics in radiation oncology: (1) improving target volume definition, (2) adoption of artificial intelligence and automation, (3) development of predictive models of biological effects for precision medicine, and (4) need for leadership. New visions and suggestions to orientate medical physics to successfully face these new challenges are summarized. We foresee that the scientific and professional challenges of our times are pushing medical physicists to accelerate toward multidisciplinarity. Medical physicists are expected to innovatively drive interactions and collaborations with other specialists outside radiation oncology while the radiation physics core will remain central. Medical physicists will retain strong and pivotal roles in quality, safety and in managing ever more complex technologies. The new challenges will require medical physicists to continuously update skills and innovate education, adapt curricula to include new fields, reinforce multi-disciplinary attitude and spirit of innovation. These challenges require visionary and open leadership, which is able to merge established roles with the exciting new fields where medical physics should increasingly contribute. (C) 2020 Elsevier B.V. All rights reserved.",
keywords = "Medical physics, Radiation oncology, AI, Target definition, Radiobiology models, Leadership, RADIOTHERAPY, THERAPY, FUTURE, HEAD, RADIOGENOMICS, IRRADIATION, EDUCATION, MODELS, IMPACT, VOLUME",
author = "Claudio Fiorino and Robert Jeraj and Clark, {Catharine H.} and Cristina Garibaldi and Dietmar Georg and Ludvig Muren and {van Elmpt}, Wouter and Thomas Bortfeld and Nuria Jornet",
note = "Funding Information: The authors gratefully acknowledge all the other participants to the Budapest ESTRO think-tank meeting (October 24th 2019) on “the most provocative questions to medical physics in radiation oncology”: M. Alber, Heidelberg University Hospital, Heidelberg, Germany – A. Cortese, CEO ESTRO, Brussels, Belgium, A. Dekker, Maastricht University Medical Centre, Maastricht, The Netherlands – H. Enderling, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA – M. Guckenberger, University Hospital Z{\"u}rich, Switzerland – M. Gooding, Mirada Medical Ltd, Oxford Centre for Innovation, UK – B. Heijmen, Erasmus MC, Rotterdam, The Netherlands – Y. Jongen, IBA, Louvain-la-Neuve, Belgium – M. Kamphuis, Academic Medical Center, University of Amsterdam, The Netherlands – R. Kikinis, Harvard Medical School, Boston, USA – T. Kn{\"o}{\"o}s, Sk{\aa}ne University Hospital, Lund University, Sweden – P. Lambin, Maastricht University Medical Centre, Maastricht, The Netherlands – Y. Lievens, Ghent University Hospital and Ghent University, Ghent, Belgium – B. McClean, St Luke's Radiation Oncology Centre, Rathgar, Dublin, Ireland – B. Nailon, NHS Lothian & The University of Edinburgh, Edinburgh, UK – H. Nystr{\"o}m, Skandion Clinic, Uppsala, Sweden – U. Oelfke, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK – W. Oyen, Humanitas University and Clinical and Research Center, Milan, Italy; Rijnstate Hospital, Dept. of Radiology and Nuclear Medicine, Arnhem, The Netherlands; Radboud UMC, Dept. of Radiology and Nuclear Medicine, Nijmegen, The Netherlands – M. Schwarz, Trento Hospital and TIFPA‐INFN, Trento, Italy – FA. Siebert, University Hospital of Schleswig-Holstein, Campus Kiel, Germany – A. Simitsis, Athena Research and Innovation Center, Athens, Greece – B. Slotman, Amsterdam University Medical Centers, Amsterdam, The Netherlands – U. van der Heide, The Netherlands Cancer Institute, Amsterdam, Netherlands – V. Valentini, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy - D. Verellen, Iridium Kankernetwerk, Antwerp University, Antwerp, Belgium – B. Wouters, University of Toronto, Toronto, Canada – D. Zips, University Hospital T{\"u}bingen, T{\"u}bingen, Germany. A. Laussucq and A. Barroso (ESTRO Office) are gratefully acknowledged for their great organization and logistic support. All the people contributing in sending suggestions for the selection of the “most provocative questions” (in total, 104 contributions) are gratefully acknowledged. Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",
year = "2020",
month = dec,
doi = "10.1016/j.radonc.2020.10.001",
language = "English",
volume = "153",
pages = "7--14",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
}